GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medipost Co Ltd (XKRX:078160) » Definitions » Gross Profit

Medipost Co (XKRX:078160) Gross Profit : ₩40,184 Mil (TTM As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Medipost Co Gross Profit?

Medipost Co's gross profit for the three months ended in Dec. 2023 was ₩9,535 Mil. Medipost Co's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was ₩40,184 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Medipost Co's gross profit for the three months ended in Dec. 2023 was ₩9,535 Mil. Medipost Co's Revenue for the three months ended in Dec. 2023 was ₩17,043 Mil. Therefore, Medipost Co's Gross Margin % for the quarter that ended in Dec. 2023 was 55.95%.

Medipost Co had a gross margin of 55.95% for the quarter that ended in Dec. 2023 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Medipost Co was 63.91%. The lowest was 44.70%. And the median was 59.09%.

Warning Sign:

Medipost Co Ltd gross margin has been in long-term decline. The average rate of decline per year is -2%.


Medipost Co Gross Profit Historical Data

The historical data trend for Medipost Co's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medipost Co Gross Profit Chart

Medipost Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29,024.38 30,890.03 31,862.68 38,372.98 40,184.15

Medipost Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11,518.58 10,440.91 10,098.35 10,109.84 9,535.05

Competitive Comparison of Medipost Co's Gross Profit

For the Biotechnology subindustry, Medipost Co's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medipost Co's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medipost Co's Gross Profit distribution charts can be found below:

* The bar in red indicates where Medipost Co's Gross Profit falls into.



Medipost Co Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Medipost Co's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=68642.987 - 28458.839
=40,184

Medipost Co's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=17042.788 - 7507.74
=9,535

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩40,184 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Medipost Co's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=9,535 / 17042.788
=55.95 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Medipost Co  (XKRX:078160) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Medipost Co had a gross margin of 55.95% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Medipost Co Gross Profit Related Terms

Thank you for viewing the detailed overview of Medipost Co's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Medipost Co (XKRX:078160) Business Description

Traded in Other Exchanges
N/A
Address
21, Daewangpangyo-ro 644, Bundang-gu, Gyeonggi-do, Seongnam, KOR
Medipost Co Ltd is a Korea-based stem cell biotechnology company. The company is engaged in developing products to meet unmet medical needs. The company operates its business through four distinct segments: Stem Cell Therapeutics, Cord Blood Bank, Cosmetics, and Health Supplements. The Cord Blood Bank Division is involved in collecting and storing stem cells from the newborn's umbilical cord. The Stem Cell Therapeutics division manufactures allogeneic stem cell drug products. The Health Supplements division offers vitamins and nutritional supplements. The Cosmetics division is involved in the sales and marketing of natural cosmetics.

Medipost Co (XKRX:078160) Headlines

No Headlines